2024 年 41 巻 5 号 p. 751-754
This article reviews the novel promising therapies and clinical researches of peripheral neuropathy, focusing on four diseases which substantial development have been made recently. The results of an international collaborative study on Guillain–Barré syndrome (GBS) and new practice guidelines were published in 2023. The development of new therapeutic agents for GBS is actively underway, particularly targeting the inhibition of the complement cascade. Clinical trials of complement– and antibody–targeted agents are also ongoing for chronic inflammatory demyelinating peripheral neuropathy (CIDP). Results of clinical trials on subcutaneous IgG (SCIg) that may extend dosing intervals beyond the conventional products for CIDP have also been published. Autologous Hematopoietic Stem Cell Transplantation may be a fundamental therapy for CIDP. For IgM–related neuropathy, a study design for a prospective collaborative study to analyze prognosis was published in 2023. Clinical trials of rituximab and Bruton's tyrosine kinase (BTK) inhibitors are in progress in this disease. For ATTRv amyloidosis, a number of new nucleic acid medicines are available in clinical practice.
